Novo Nordisk Discloses Insider Trading Activity
Ticker: NONOF · Form: 6-K · Filed: Nov 8, 2024 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulatory
Related Tickers: NVO
TL;DR
Novo Nordisk execs and board members traded shares, filing shows.
AI Summary
On November 8, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on market abuse, which requires reporting of such trading activities.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading and does not indicate any new or significant risks for the company.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- November 8, 2024 (date) — Filing date and transaction disclosure date
- Regulation No. 596/2014 (regulation) — Governing market abuse and insider trading disclosures
- Article 19 (regulation) — Specific article requiring disclosure of insider transactions
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this company announcement made?
The company announcement was made on November 8, 2024.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Is Novo Nordisk filing an annual report on Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under cover of Form 20-F.
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-11-08 16:46:16
Filing Documents
- f6k_110824.htm (6-K) — 24KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006182.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 8, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer